Join to View Full Profile
3515 east spring streetSeattle, WA 98122
Phone+1 206-669-7833
Dr. Singer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1972 - 1975
University of ChicagoResidency, Internal Medicine, 1968 - 1970
State University of New York Downstate Medical Center College of MedicineClass of 1968
Certifications & Licensure
WA State Medical License 1972 - 2020
Awards, Honors, & Recognition
- AOA SUNYDownstate, 1967
- Elected Member The American Society for Clinical Investigation, 1987
Clinical Trials
- CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL Start of enrollment: 2007 Sep 01
Publications & Presentations
PubMed
- 16 citationsPixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation...Ruth Pettengell, Monika Długosz-Danecka, David Andorsky, David Belada, Pencho Georgiev
British Journal of Haematology. 2020-01-01 - Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133].Jonathan H. Seltzer, Gary Gintant, Laleh Amiri-Kordestani, Jack W. Singer, Luana Pesco Koplowitz
American Heart Journal. 2019-12-01 - 35 citationsComparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.Jack W. Singer, Suliman Al-Fayoumi, Jason Taylor, Sharlene Velichko, Alison O'Mahony
Plos One. 2019-09-27
Journal Articles
- Inhibition of Interleukin-1 Receptor-Associated Kinase 1 (IRAK1) as a Therapeutic StrategyAngela Fleischman, John O. Mascarenhas, Jack W. Singer, Oncotarget
Grant Support
- Defining An Oral Therapeutic For Multiple SclerosisNational Institute Of Neurological Disorders And Stroke2000
- Growth Factors In Marrow TransplantationNational Cancer Institute1992–1996
- Growth Factors In Autologous Marrow TransplantationNational Cancer Institute1992–1996
- Recombinant Hematopoietic Growth Factaors In Aht--Effect Of Hematopoietic ProgenaNational Cancer Institute1989–1991
- Studies Of The In Vitro Hematopoietic MicroenvironmentNational Heart, Lung, And Blood Institute1987–1991
- Adult Leukemia Research CenterNational Cancer Institute1987–1991
- In Vitro Hematopoeisis During Marrow TransplantationNational Cancer Institute1985–1986
- In Vitro Microenvironment In Aplastic AnemiaNational Heart, Lung, And Blood Institute1985
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
